Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma

Genome Medicine

Volumn 4, Issue 12, 2012, Pages

  Aoki, Yuka ^a   Nojima, Masanori ^a   Suzuki, Hiromu ^a   Yasui, Hiroshi ^a   Maruyama, Reo ^a   Yamamoto, Eiichiro ^a   Ashida, Masami ^a   Itagaki, Mitsuhiro ^b   Asaoku, Hideki ^b   Ikeda, Hiroshi ^a   Hayashi, Toshiaki ^a   Imai, Kohzoh ^c   Mori, Mitsuru ^a   Tokino, Takashi ^a   Ishida, Tadao ^a   Toyota, Minoru ^a   Shinomura, Yasuhisa ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Common breakpoints; Global hypomethylation; LINE 1; Multiple myeloma; Repetitive elements

Indexed keywords

METHYL CPG BINDING PROTEIN;

5' UNTRANSLATED REGION; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DISEASE COURSE; DNA METHYLATION; DNA STRUCTURE; GENE IDENTIFICATION; GENE LOCUS; HUMAN; INTERSPERSED REPEAT; LONG INTERSPERSED NUCLEAR ELEMENT 1; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

EID: 84871369855     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm402     Document Type: Article

References (52)

1. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010, 116:e56-65. 10.1182/blood-2010-04-279596, 20616218.
2. Avet Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495. 10.1182/blood-2006-08-040410, 17209057.
3. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028. 10.1182/blood-2005-11-013458, 1895543, 16728703.
4. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002, 99:2185-2191. 10.1182/blood.V99.6.2185, 11877296.
5. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9:313-325. 10.1016/j.ccr.2006.03.019, 16616336.
6. Yasui H, Hideshima T, Richardson PG, Anderson KC. Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol 2006, 7:381-393. 10.2174/138920106778521569, 17076653.
7. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications:. Blood 2004, 104:607-618. 10.1182/blood-2004-01-0037, 15090448.
8. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997, 89:2500-2506.
9. Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, Bauters F, Fenaux P, Quesnel B. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001, 98:244-246. 10.1182/blood.V98.1.244, 11418489.
10. Gonzalez-Paz N, Chang WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, Gertz M, Lacy M, Dispenzieri A, Greipp PR, Fonseca R. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109:1228-1232.
11. Murai M, Toyota M, Satoh A, Suzuki H, Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, Issa JP, Hinoda Y, Tokino T, Imai K. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 2005, 92:1165-1172. 10.1038/sj.bjc.6602422, 2361956, 15756280.
12. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, Zielinski CC, Drach J, Zochbauer Muller S. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008, 68:44-54. 10.1158/0008-5472.CAN-07-2531, 18172295.
13. Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, Mori M, Imai K, Tokino T, Ishida T, Toyota M, Shinomura Y. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 2009, 15:4356-4364. 10.1158/1078-0432.CCR-08-3336, 19549772.
14. Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M, Nucci M, Renault IZ. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 2010, 91:87-96. 10.1007/s12185-009-0459-2, 20037750.
15. Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res 2010, 70:6934-6944. 10.1158/0008-5472.CAN-10-0282, 20736376.
16. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011, 117:553-562. 10.1182/blood-2010-04-279539, 20944071.
17. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011, 117:211-220. 10.1182/blood-2010-07-298349, 3037745, 20974671.
18. De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg Wiklund H, Vanderkerken K. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 2010, 115:2430-2440. 10.1182/blood-2009-07-232801, 20086250.
19. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92. 10.1038/301089a0, 6185846.
20. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005, 33:6823-6836. 10.1093/nar/gki987, 1301596, 16326863.
21. Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. Nat Rev Genet 2009, 10:691-703. 10.1038/nrg2640, 2884099, 19763152.
22. Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D, Garcia-Manero G, Liang G, Yang AS. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer 2009, 125:723-729. 10.1002/ijc.24384, 19437537.
23. Widschwendter M, Jiang G, Woods C, Muller HM, Fiegl H, Goebel G, Marth C, Muller-Holzner E, Zeimet AG, Laird PW, Ehrlich M. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004, 64:4472-4480. 10.1158/0008-5472.CAN-04-0238, 15231656.
24. Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, Muller-Holzner E, Widschwendter M, Ehrlich M. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 2004, 3:1225-1231. 10.4161/cbt.3.12.1222, 15539937.
25. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008, 100:1734-1738. 10.1093/jnci/djn359, 2639290, 19033568.
26. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, Gorgoulis V, Field JK, Liloglou T. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2009, 124:81-87. 10.1002/ijc.23849, 18823011.
27. Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, Iwaki H, Nobuoka T, Nishida T, Miyazaki Y, Takamaru H, Yamamoto E, Yamamoto H, Tokino T, Hasegawa T, Hirata K, Imai K, Toyota M, Shinomura Y. A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clin Cancer Res 2010, 16:5114-5123. 10.1158/1078-0432.CCR-10-0581, 20978145.
28. Johns Hopkins University. Bowtie An ultrafast, memory-efficient short read aligner. Johns Hopkins University. Bowtie., http://bowtie-bio.sourceforge.net/index.shtml
29. University of California Santa Cruz UCSC Genome Bioinformatics. University of California Santa Cruz., http://genome.ucsc.edu/
30. Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, Gu H, Jager N, Gnirke A, Stunnenberg HG, Meissner A. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol 2010, 28:1106-1114. 10.1038/nbt.1681, 3066564, 20852634.
31. Wallace N, Wagstaff BJ, Deininger PL, Roy-Engel AM. LINE-1 ORF1 protein enhances Alu SINE Retrotransposition. Gene 2008, 419:1-6. 10.1016/j.gene.2008.04.007, 2491492, 18534786.
32. She X, Horvath JE, Jiang Z, Liu G, Furey TS, Christ L, Clark R, Graves T, Gulden CL, Alkan C, Bailey JA, Sahinalp C, Rocchi M, Haussler D, Wilson RK, Miller W, Schwartz S, Eichler EE. The structure and evolution of centromeric transition regions within the human genome. Nature 2004, 430:857-864. 10.1038/nature02806, 15318213.
33. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet 2002, 3:370-379. 10.1038/nrg798, 11988762.
34. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ, Giovannucci EL, Fuchs CS, Ogino S. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010, 9:125. 10.1186/1476-4598-9-125, 2892454, 20507599.
35. Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J, Yang AS, Yan PS, Huang TH, Tajara EH, Issa JP. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2007, 2:e399. 10.1371/journal.pone.0000399, 1851990, 17476321.
36. Zeimet AG, Fiegl H, Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Mueller-Holzner E, Ehrlich M, Marth C. DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol 2011, 121:24-31. 10.1016/j.ygyno.2010.12.332, 3062717, 21251700.
37. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One 2011, 6:e23332. 10.1371/journal.pone.0023332, 3150434, 21829728.
38. Weber B, Kimhi S, Howard G, Eden A, Lyko F. Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene 2010, 29:5775-5784. 10.1038/onc.2010.227, 20562909.
39. Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA, Liang G. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 2010, 6:e1000917. 10.1371/journal.pgen.1000917, 2858672, 20421991.
40. Bollati V, Fabris S, Pegoraro V, Ronchetti D, Mosca L, Deliliers GL, Motta V, Bertazzi PA, Baccarelli A, Neri A. Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis 2009, 30:1330-1335. 10.1093/carcin/bgp149, 19531770.
41. Yoshida T, Yamashita S, Takamura-Enya T, Niwa T, Ando T, Enomoto S, Maekita T, Nakazawa K, Tatematsu M, Ichinose M, Ushijima T. Alu and Satalpha hypomethylation in Helicobacter pylori-infected gastric mucosae. Int J Cancer 2011, 128:33-39. 10.1002/ijc.25534, 20602342.
42. Yamamoto E, Toyota M, Suzuki H, Kondo Y, Sanomura T, Murayama Y, Ohe-Toyota M, Maruyama R, Nojima M, Ashida M, Fujii K, Sasaki Y, Hayashi N, Mori M, Imai K, Tokino T, Shinomura Y. LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev 2008, 17:2555-2564. 10.1158/1055-9965.EPI-08-0112, 18842996.
43. Han JS, Szak ST, Boeke JD. Transcriptional disruption by the L1 retrotransposon and implications for mammalian transcriptomes. Nature 2004, 429:268-274. 10.1038/nature02536, 15152245.
44. Iskow RC, McCabe MT, Mills RE, Torene S, Pittard WS, Neuwald AF, Van Meir EG, Vertino PM, Devine SE. Natural mutagenesis of human genomes by endogenous retrotransposons. Cell 2010, 141:1253-1261. 10.1016/j.cell.2010.05.020, 2943760, 20603005.
45. Glover TW, Berger C, Coyle J, Echo B. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 1984, 67:136-142. 10.1007/BF00272988, 6430783.
46. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 2003, 100:5956-5961. 10.1073/pnas.0931262100, 156308, 12719539.
47. Jiang Y, Lucas I, Young DJ, Davis EM, Karrison T, Rest JS, Le Beau MM. Common fragile sites are characterized by histone hypoacetylation. Hum Mol Genet 2009, 18:4501-4512. 10.1093/hmg/ddp410, 2773265, 19717471.
48. Morelli C, Karayianni E, Magnanini C, Mungall AJ, Thorland E, Negrini M, Smith DI, Barbanti Brodano G. Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene 2002, 21:7266-7276. 10.1038/sj.onc.1205573, 12370818.
49. Avet Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009, 27:4585-4590. 10.1200/JCO.2008.20.6136, 2754906, 19687334.
50. Saez B, Martin Subero JI, Largo C, Martin MC, Odero MD, Prosper F, Siebert R, Calasanz MJ, Cigudosa JC. Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses. Cancer Genet Cytogenet 2006, 169:143-149. 10.1016/j.cancergencyto.2006.04.008, 16938572.
51. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001, 61:6640-6648.
52. Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DA. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 2011, 331:593-596. 10.1126/science.1200801, 21233348.